mosunetuzumab + polatuzumab vedotin + axicabtagene ciloleucel

**Mosunetuzumab + polatuzumab vedotin + axicabtagene ciloleucel** is an investigational triplet combination therapy for relapsed/refractory B-cell lymphomas, particularly large B-cell lymphoma (LBCL). It pairs **axicabtagene ciloleucel** (axi-cel), a CD19-directed CAR T-cell therapy that engineers patient T cells to target and eliminate malignant B cells, with pretreatment and consolidation using **mosunetuzumab**, a CD20xCD3 bispecific T-cell engager antibody that recruits T cells to lyse CD20-expressing tumor cells, and **polatuzumab vedotin**, an anti-CD79b antibody-drug conjugate (ADC) that delivers monomethyl auristatin E (MMAE), a microtubule inhibitor, to induce apoptosis in B cells. Developed primarily by Roche/Genentech, this regimen aims to deepen responses post-CAR T by reducing tumor burden upfront and preventing relapse via bispecific and ADC activity; early data from phase 1/2 trials show high complete response rates (e.g., at day+90).[1][5][9]